ArticleJournal of community genetics2026
The effect of sample type on genetic testing completion in pediatric congenital hearing loss patients.
Article in Journal of community genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital pediatric hearing loss can be linked to a genetic cause in about 60% of cases. Genetic testing (GT) for this condition can be complicated by the availability of blood draw services and the patient's amenability to this procedure. The primary objective of this study was to assess whether GT sample collection method influences the percentage of completed tests in pediatric patients with congenital, non-syndromic sensorineural hearing loss. This was a retrospective chart review of patients at a tertiary pediatric otolaryngology clinic who had GT ordered through blood draw from May 2022-April 2023 and patients who had GT ordered through buccal swab from June 2023-May 2024. Patients were offered a testing method based on availability at our institution during the time period studied. The primary endpoint was completion of GT. Additional data collected included demographic patient characteristics, average turnaround time for GT completion, and GT results. Each cohort had a GT completion percentage of approximately 93%. Almost twice as many patients had GT ordered via buccal swab (148/227) than blood sample (79/227: p < 0.05). There was no difference in GT results between cohorts. The observed similarities in GT completion of the cohorts in this study suggests that barriers to GT completion may not be the sample type alone, but rather a more complex set of factors that may affect family decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.